株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌性疼痛の世界市場 - 薬剤の種類別 (オピオイド系/非オピオイド系鎮痛剤、神経遮断薬)・症状別 (肺がん、大腸がん、乳がん、前立腺がん、血液のがんなど):市場機会と将来予測

Cancer Pain Market by Drug Type (Opioids, Non-Opioids, and Nerve Blockers) and Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

発行 Allied Market Research 商品コード 763995
出版日 ページ情報 英文 177 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
癌性疼痛の世界市場 - 薬剤の種類別 (オピオイド系/非オピオイド系鎮痛剤、神経遮断薬)・症状別 (肺がん、大腸がん、乳がん、前立腺がん、血液のがんなど):市場機会と将来予測 Cancer Pain Market by Drug Type (Opioids, Non-Opioids, and Nerve Blockers) and Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
出版日: 2018年12月18日 ページ情報: 英文 177 Pages
概要

当レポートでは、世界のがん性疼痛の治療薬の市場について分析し、市場の基本構造や最新情勢、主な促進・抑制要因と市場求心力、市場規模の動向と見通し (今後8年間分)、薬剤別・疾患別・地域別の詳細動向、主要企業のプロファイルなどについて調査しております。

第1章 イントロダクション

第2章 エグゼクティブ・サマリー

第3章 市場概要

  • 市場の定義と範囲
  • 分析概略
    • 主な投資財源
    • 主な成功戦略
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場のダイナミクス
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 影響度の分析

第4章 癌性疼痛市場:薬剤の種類別

  • 概要
    • 市場規模とその予測
  • オピオイド系鎮痛剤
    • 市場の主な動向、成長要因、市場機会
    • 市場規模とその予測:種類別
      • モルヒネ
      • フェンタニル
      • その他
    • 市場規模とその予測:地域別
    • 市場分析:国別
  • 非オピオイド系鎮痛剤
    • 市場の主な動向、成長要因、市場機会
    • 市場規模とその予測:種類別
      • アセトアミノフェン
      • NSAID (非ステロイド性抗炎症薬)
      • その他
    • 市場規模とその予測:地域別
    • 市場分析:国別
  • 神経遮断薬 (ブロッカー)
    • 市場の主な動向、成長要因、市場機会
    • 市場規模とその予測:地域別
    • 市場分析:国別

第5章 癌性疼痛市場:疾患別

  • 概要
  • 肺がん
    • 市場規模とその予測
    • 市場分析:国別
  • 大腸がん
  • 乳がん
  • 前立腺がん
  • 血液のがん
  • その他

第6章 癌性疼痛市場:地域

  • 概要
  • 北米市場 (米国・カナダ・メキシコ)
    • 市場の主な動向、成長要因、市場機会
    • 市場規模とその予測:国別
      • 各国市場:種類別、症状別
  • 欧州市場 (ドイツ・フランス・英国・イタリア・スペインなど)
  • アジア太平洋地域市場 (日本・中国・オーストラリア・インドなど)
  • ラテンアメリカ・中東・アフリカ市場 (LAMEA:ブラジル・サウジアラビア・南アフリカなど)

第7章 企業プロファイル

  • AOXING PHARMACEUTICAL COMPANY, INC.
    • 基本データ
    • 企業概要
    • 事業部門
    • 製品ポートフォリオ
    • 業績
  • BIODELIVERY SCIENCES INTERNATIONAL, INC.
  • 第一三共
  • GRNENTHAL PHARMA GmbH & CO. KG
  • 久光製薬
  • INSYS THERAPEUTICS, INC.
  • MUNDIPHARMA INTERNATIONAL LIMITED
  • OREXO AB
  • PFIZER INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
図表

List of Tables

LIST OF TABLES

  • TABLE 01. GLOBAL CANCER PAIN MARKET, BY DRUG TYPE, 20172025 ($MILLION)
  • TABLE 02. OPIOIDS MARKET, BY TYPE, 20172025 ($MILLION)
  • TABLE 03. OPIOIDS MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 04. NON-OPIOIDS MARKET, BY TYPE, 20172025 ($MILLION)
  • TABLE 05. NON-OPIOIDS MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 06. NERVE BLOCKERS MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 07. GLOBAL CANCER PAIN MARKET, BY APPLICATION, 20172025 ($MILLION)
  • TABLE 08. LUNG CANCER PAIN MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 09. COLORECTAL CANCER PAIN MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 10. BREAST CANCER PAIN MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 11. PROSTATE CANCER PAIN MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 12. BLOOD CANCER PAIN MARKET, BY REGION, 20172025 ($MILLION)
  • TABLE 13. CANCER PAIN MARKET FOR OTHER DISEASE INDICATION, BY REGION, 20172025 ($MILLION)
  • TABLE 14. CANCER PAIN MARKET REVENUE, BY REGION, 20172025 ($MILLION)
  • TABLE 15. NORTH AMERICA CANCER PAIN MARKET REVENUE, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 16. U.S. CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 17. U.S. CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 18. CANADA CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 19. CANADA CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 20. MEXICO CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 21. MEXICO CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 22. NORTH AMERICA CANCER PAIN MARKET REVENUE, BY TYPE, 20172025 ($MILLION)
  • TABLE 23. NORTH AMERICA CANCER PAIN MARKET REVENUE, BY DISEASE INDICATION, 20172025 ($MILLION)
  • TABLE 24. EUROPE CANCER PAIN MARKET REVENUE, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 25. GERMANY CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 26. GERMANY CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 27. FRANCE CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 28. FRANCE CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 29. UK CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 30. UK CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 31. ITALY CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 32. ITALY CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 33. SPAIN CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 34. SPAIN CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 35. REST OF EUROPE CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 36. REST OF EUROPE CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 37. EUROPE CANCER PAIN MARKET REVENUE, BY TYPE, 20172025 ($MILLION)
  • TABLE 38. EUROPE CANCER PAIN MARKET REVENUE, BY DISEASE INDICATION, 20172025 ($MILLION)
  • TABLE 39. ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 40. JAPAN CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 41. JAPAN CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 42. CHINA CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 43. CHINA CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 44. AUSTRALIA CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 45. AUSTRALIA CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 46. INDIA CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 47. INDIA CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 48. REST OF ASIA- PACIFIC CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 49. REST OF ASIA- PACIFIC CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY TYPE, 20172025 ($MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY DISEASE INDICATION, 20172025 ($MILLION)
  • TABLE 52. LAMEA CANCER PAIN MARKET REVENUE, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 53. BRAZIL CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 54. BRAZIL CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 55. SAUDI ARABIA CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 56. SAUDI ARABIA CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 57. SOUTH AFRICA CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 58. SOUTH AFRICA CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 59. REST OF LAMEA CANCER PAIN MARKET, BY TYPE, 20162023 ($MILLION)
  • TABLE 60. REST OF LAMEA CANCER PAIN MARKET, BY DISEASE INDICATION, 20162023 ($MILLION)
  • TABLE 61. LAMEA CANCER PAIN MARKET REVENUE, BY TYPE, 20172025 ($MILLION)
  • TABLE 62. LAMEA CANCER PAIN MARKET VOLUME, BY DISEASE INDICATION, 20172025 (UNITS)
  • TABLE 63. AOXING PHARM: COMPANY SNAPSHOT
  • TABLE 64. AOXING PHARM: OPERATING SEGMENTS
  • TABLE 65. AOXING PHARM: PRODUCT PORTFOLIO
  • TABLE 66. BDSI: COMPANY SNAPSHOT
  • TABLE 67. BDSI: OPERATING SEGMENTS
  • TABLE 68. BDSI: PRODUCT PORTFOLIO
  • TABLE 69. DAIICHI SANKYO: COMPANY SNAPSHOT
  • TABLE 70. DAIICHI SANKYO: PRODUCT PORTFOLIO
  • TABLE 71. GRNENTHAL: COMPANY SNAPSHOT
  • TABLE 72. GRNENTHAL: PRODUCT PORTFOLIO
  • TABLE 73. HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT
  • TABLE 74. HISAMITSU PHARMACEUTICAL: OPERATING SEGMENTS
  • TABLE 75. HISAMITSU PHARMACEUTICAL: PRODUCT PORTFOLIO
  • TABLE 76. INSYS: COMPANY SNAPSHOT
  • TABLE 77. INSYS: OPERATING SEGMENTS
  • TABLE 78. INSYS: PRODUCT PORTFOLIO
  • TABLE 79. MUNDIPHARMA: COMPANY SNAPSHOT
  • TABLE 80. MUNDIPHARMA: PRODUCT PORTFOLIO
  • TABLE 81. OREXO: COMPANY SNAPSHOT
  • TABLE 82. OREXO: OPERATING SEGMENTS
  • TABLE 83. OREXO: PRODUCT PORTFOLIO
  • TABLE 84. PFIZER: COMPANY SNAPSHOT
  • TABLE 85. PFIZER: OPERATING SEGMENTS
  • TABLE 86. PFIZER: PRODUCT PORTFOLIO
  • TABLE 87. TEVA: COMPANY SNAPSHOT
  • TABLE 88. TEVA: OPERATING SEGMENTS
  • TABLE 89. TEVA: PRODUCT PORTFOLIO

List of Figures

LIST OF FIGURES

  • FIGURE 01. GLOBAL CANCER PAIN MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP PLAYER POSITIONING, 2017
  • FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
  • FIGURE 05. IMPACT ANALYSES
  • FIGURE 06. MORPHINE MARKET FOR CANCER PAIN, 20172025 ($MILLION)
  • FIGURE 07. FENTANYL MARKET FOR CANCER PAIN, 20172025 ($MILLION)
  • FIGURE 08. OTHERS MARKET FOR CANCER PAIN, 20172025 ($MILLION)
  • FIGURE 09. COMPARATIVE ANALYSIS OF OPIOIDS MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 10. ACETAMINOPHEN MARKET FOR CANCER PAIN, 20172025 ($MILLION)
  • FIGURE 11. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR CANCER PAIN, 20172025 ($MILLION)
  • FIGURE 12. COMPARATIVE ANALYSIS OF NON-OPIOIDS, MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 13. COMPARATIVE ANALYSIS OF NERVE BLOCKERS MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 14. COMPARATIVE ANALYSIS OF LUNG CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 15. COMPARATIVE ANALYSIS OF COLORECTAL CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 16. COMPARATIVE ANALYSIS OF BREAST CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 17. COMPARATIVE ANALYSIS OF PROSTATE CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 18. COMPARATIVE ANALYSIS OF BLOOD CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 19. COMPARATIVE ANALYSIS OF CANCER PAIN MARKET FOR OTHER INDICATION MARKET, BY COUNTRY, 2017 & 2025 (%)
  • FIGURE 20. AOXING PHARM: REVENUE, 20152017 ($MILLION)
  • FIGURE 21. BDSI: NET SALES, 20152017 ($MILLION)
  • FIGURE 22. DAIICHI SANKYO: NET SALES, 20152017 ($MILLION)
  • FIGURE 23. HISAMITSU PHARMACEUTICAL REVENUE, 20152017 ($MILLION)
  • FIGURE 24. HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY BUSINESS SEGMENT, 2017 (%)
  • FIGURE 25. HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 26. INSYS: NET SALES, 20152017 ($MILLION)
  • FIGURE 27. OREXO: REVENUE, 20152017 ($MILLION)
  • FIGURE 28. OREXO: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 29. PFIZER: REVENUE, 20152017 ($MILLION)
  • FIGURE 30. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 31. PFIZER: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 32. TEVA: REVENUE, 20152017 ($MILLION)
  • FIGURE 33. TEVA: REVENUE BY SEGMENT, 2017 (%)
  • FIGURE 34. TEVA: REVENUE SHARE BY REGION, 2017 (%)
目次
Product Code: LI_185123

Title:
Cancer Pain Market by Drug Type (Opioids, Non-Opioids, and Nerve Blockers) and Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025.

Cancer Pain Market Overview:

The global cancer pain market generated $5,285 million in 2017, and is projected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

Cancer pain can be due to the disease condition itself or may be due to the associated treatments such as surgeries, chemotherapy, and other therapies. There is surge in the demand for cancer pain drugs owing to the growth in incidence of different forms of cancer, higher number of R&D studies to develop cancer pain therapeutics, and increase in adoption of cancer pain drugs. In addition, growth in the geriatric population and wide availability of cancer pain drugs further drive the market growth. However, adverse effects associated with cancer pain are projected to impede the market growth.

The global cancer pain market is segmented based on drug type, disease indication, and region. Based on drug type, the market is classified into opioids, non-opioids, and nerve blockers. According to the disease indication, the market is categorized into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).

Key Benefits for Cancer Pain Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.

A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Cancer Pain Key Market Segments:

By Drug Type

  • Opioids
  • Non-Opioids
  • Nerve Blockers

By Application

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin Lymphoma
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List Of Key Players Profiled in the Report:

  • Aoxing Pharmaceutical Company, Inc.
  • BioDelivery Sciences International, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Grunenthal Pharma GmbH & Co. KG
  • Hisamitsu Pharmaceutical Co, Inc.
  • Insys Therapeutics, Inc.
  • Mundipharma International Limited
  • Orexo AB
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited

List Of Other Players in the Value Chain(These players are not profiled in the report. The same will be included on request.)

  • Eli Lilly and Company
  • Galena Biopharma
  • Kyowa Kirin International plc
  • Meda Pharmaceuticals

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
    • 2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top player positioning
  • 3.3. Market dynamics
    • 3.3.1. Drivers
      • 3.3.1.1. Rise in incidence of cancer across the globe
      • 3.3.1.2. Surge in global geriatric population
      • 3.3.1.3. Increase in healthcare expenditure worldwide
    • 3.3.2. Restraints
      • 3.3.2.1. Adverse effects associated with the use of drugs employed in cancer pain management
    • 3.3.3. Opportunities
      • 3.3.3.1. Increase in number of pipeline drugs
      • 3.3.3.2. Growth opportunities in emerging markets
    • 3.3.4. Impact analyses

CHAPTER 4: CANCER PAIN MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Opioids
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by type
      • 4.2.2.1. Morphine
      • 4.2.2.1.1. Market size and forecast
      • 4.2.2.2. Fentanyl
      • 4.2.2.2.1. Market size and forecast
      • 4.2.2.3. Others
      • 4.2.2.3.1. Market size and forecast
    • 4.2.3. Market size and forecast, by region
    • 4.2.4. Market analysis, by country
  • 4.3. Non-opioids
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by type
      • 4.3.2.1. Acetaminophen
      • 4.3.2.1.1. Market size and forecast
      • 4.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 4.3.2.2.1. Market size and forecast
    • 4.3.3. Market size and forecast, by region
    • 4.3.4. Market analysis, by country
  • 4.4. Nerve blockers
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market analysis, by country

CHAPTER 5: CANCER PAIN MARKET, BY DISEASE INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Lung cancer
    • 5.2.1. Market size and forecast
    • 5.2.2. Market analysis, by country
  • 5.3. Colorectal cancer
    • 5.3.1. Market size and forecast
    • 5.3.2. Market analysis, by country
  • 5.4. Breast cancer
    • 5.4.1. Market size and forecast
    • 5.4.2. Market analysis, by country
  • 5.5. Prostate cancer
    • 5.5.1. Market size and forecast
    • 5.5.2. Market analysis, by country
  • 5.6. Blood cancer
    • 5.6.1. Market size and forecast
    • 5.6.2. Market analysis, by country
  • 5.7. Others
    • 5.7.1. Market size and forecast
    • 5.7.2. Market analysis, by country

CHAPTER 6: CANCER PAIN MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. Market size and forecast, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. market size and forecast, by type
      • 6.2.2.1.2. U.S. market size and forecast, by disease indication
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada market size and forecast, by type
      • 6.2.2.2.2. Canada market size and forecast, by disease indication
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Mexico market size and forecast, by type
      • 6.2.2.3.2. Mexico market size and forecast, by disease indication
    • 6.2.3. Market size and forecast, by type
    • 6.2.4. Market size and forecast, by disease indication
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Market size and forecast, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany market size and forecast, by type
      • 6.3.2.1.2. Germany market size and forecast, by disease indication
      • 6.3.2.2. France
      • 6.3.2.2.1. France market size and forecast, by type
      • 6.3.2.2.2. France market size and forecast, by disease indication
      • 6.3.2.3. UK
      • 6.3.2.3.1. UK market size and forecast, by type
      • 6.3.2.3.2. UK market size and forecast, by disease indication
      • 6.3.2.4. Italy
      • 6.3.2.4.1. Italy market size and forecast, by type
      • 6.3.2.4.2. Italy market size and forecast, by disease indication
      • 6.3.2.5. Spain
      • 6.3.2.5.1. Spain market size and forecast, by type
      • 6.3.2.5.2. Spain market size and forecast, by disease indication
      • 6.3.2.6. Rest of Europe
      • 6.3.2.6.1. Rest of Europe market size and forecast, by type
      • 6.3.2.6.2. Rest of Europe market size and forecast, by disease indication
    • 6.3.3. Market size and forecast, by type
    • 6.3.4. Market size and forecast, by disease indication
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan market size and forecast, by type
      • 6.4.2.1.2. Japan market size and forecast, by disease indication
      • 6.4.2.2. China
      • 6.4.2.2.1. China market size and forecast, by type
      • 6.4.2.2.2. China market size and forecast, by disease indication
      • 6.4.2.3. Australia
      • 6.4.2.3.1. Australia market size and forecast, by type
      • 6.4.2.3.2. Australia market size and forecast, by disease indication
      • 6.4.2.4. India
      • 6.4.2.4.1. India market size and forecast, by type
      • 6.4.2.4.2. India market size and forecast, by disease indication
      • 6.4.2.5. Rest of Asia-Pacific
      • 6.4.2.5.1. Rest of Asia- Pacific market size and forecast, by type
      • 6.4.2.5.2. Rest of Asia- Pacific market size and forecast, by disease indication
    • 6.4.3. Market size and forecast, by type
    • 6.4.4. Market size and forecast, by disease indication
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. Market size and forecast, by country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Brazil market size and forecast, by type
      • 6.5.2.1.2. Brazil market size and forecast, by disease indication
      • 6.5.2.2. Saudi Arabia
      • 6.5.2.2.1. Saudi Arabia market size and forecast, by type
      • 6.5.2.2.2. Saudi Arabia market size and forecast, by disease indication
      • 6.5.2.3. South Africa
      • 6.5.2.3.1. South Africa market size and forecast, by type
      • 6.5.2.3.2. South Africa market size and forecast, by disease indication
      • 6.5.2.4. Rest of LAMEA
      • 6.5.2.4.1. Rest of LAMEA market size and forecast, by type
      • 6.5.2.4.2. Rest of LAMEA market size and forecast, by disease indication
    • 6.5.3. Market size and forecast, by type
    • 6.5.4. Market volume and forecast, by disease indication

CHAPTER 7: COMPANY PROFILES

  • 7.1. AOXING PHARMACEUTICAL COMPANY, INC.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product Portfolio
    • 7.1.5. Business performance
  • 7.2. BIODELIVERY SCIENCES INTERNATIONAL, INC.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product Portfolio
    • 7.2.5. Business performance
  • 7.3. DAIICHI SANKYO CO., LTD.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Product Portfolio
    • 7.3.4. Business performance
    • 7.3.5. Key strategic moves and developments
  • 7.4. GRNENTHAL PHARMA GmbH & CO. KG
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Product Portfolio
  • 7.5. HISAMITSU PHARMACEUTICAL CO., INC.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
  • 7.6. INSYS THERAPEUTICS, INC.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product portfolio
    • 7.6.5. Business performance
  • 7.7. MUNDIPHARMA INTERNATIONAL LIMITED
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Product Portfolio
  • 7.8. OREXO AB
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product Portfolio
    • 7.8.5. Business performance
  • 7.9. PFIZER INC.
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product Portfolio
    • 7.9.5. Business performance
  • 7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product Portfolio
    • 7.10.5. Business performance
Back to Top